Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD).

Locations

9 United States sites

3 Turkey sites

2 Lebanon sites

1 Italy site

1 Kenya site

1 Oman site

Age

12 Years to Years

Phase

Phase 3

LEARN MORE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD).

Locations

14 United States sites

5 Kenya sites

4 Turkey sites

3 France sites

3 Italy sites

2 Brazil sites

2 Lebanon sites

1 Germany site

1 Saudi Arabia site

1 Oman site

1 Tanzania site

1 United Kingdom site

Age

12 Years to Years

Genotypes

3

Phase

Phase 3

LEARN MORE
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Locations

3 United States sites

3 Brazil sites

3 Turkey sites

2 Belgium sites

2 Italy sites

2 Lebanon sites

1 Colombia site

1 France site

1 Oman site

1 Germany site

1 Spain site

Age

6 Months to Years

Phase

Phase 4

LEARN MORE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.

Locations

17 United States sites

5 Nigeria sites

4 Egypt sites

4 United Kingdom sites

3 Italy sites

3 Kenya sites

2 Ghana sites

2 Oman sites

2 Saudi Arabia sites

1 France site

Age

2 Years to 14 Years Years

Phase

Phase 3

LEARN MORE